London: The UK has approved the Coronavirus vaccine of Pfizer and BioNTech Coronavirus Vaccine. With this, Britain has become the first western country to approve the Covid-19 vaccine. According to the information, the vaccination can be started from the National Health Service (NHS) personnel in the UK from December 7. Earlier, Russia has approved the use of its Sputnik-V vaccine. According to Health Secretary Matt Hancock, this vaccine will first be made available to the elderly only.
Britain has ordered 40 million doses of the two-shot vaccine of Pfizer and BioNotech. This vaccine has been found to be more than 95% effective in preventing infection. Britain’s Foreign Minister Dominic Raab had already said in an interview that the vaccine would be made available in Britain from next week.
The Pfizer-BioNotech coronavirus vaccine has been approved and approved by the UK medical regulator, Medicine and Healthcare Products Regulatory Agency (MHRA). The agency is also in the process of determining whether the vaccines of Oxford University and AstraZeneca meet the stringent safety standards or not. If something happens as per the plan and the vaccine developed by Pfizer and Bioentech gets the approval of the authority, then within a few hours the vaccine will be dispensed and vaccinated.
New genetic technology used in Pfizer
Pfizer’s vaccine is different from traditional vaccines using a new genetic technology that is at the forefront of science. Actually, mRNA vaccine is special. The use of synthetic mRNA activates the immune system and fights the virus. Traditionally, the vaccine carries a small portion of the virus that spreads the disease into the human body. But the mRNA vaccine tricks our body into making some viral protein by itself.
Pfizer’s vaccine use is challenging
Let me tell you that AIIMS director Dr. Randeep Guleria said on Wednesday that storage of the potential Covid-19 vaccine developed by the pharmaceutical company Pfizer requires a temperature of minus 70 degrees Celsius and this is in developing countries like India, especially There is a big challenge to supply vaccines in towns and rural areas. Guleria says that most vaccines in India are kept at a temperature of two to eight degrees Celsius. In most parts of the country, vaccines can be kept in cold chains at temperatures as low as minus 25 degrees Celsius.
He said that there are no cold storage chains with such low temperatures in the towns, villages, and remote areas of the country, in such a situation, it will be a big challenge to get the vaccine there. Guleria, however, stated that the vaccine is capable of protecting up to 90 percent of coronavirus infections in the first-stage results announced by Pfizer Inc. and BioNotech SE after Phase III trials of the vaccine and is encouraging information. Guleria emphasized that the data released by the companies developing the vaccine needed to be studied and to see how long the immunity developed from it would remain effective.
